Robert A. Gross, MD, PhD, FAAN, Editor-in-Chief, *Neurology*[®]

Notable in *Neurology* this week

This issue features an article that documents an increase in interfacility emergency department transfers for patients with TIA and stroke, and another that describes visible and invisible disabilities in adult patients with arthrogryposis multiplex congenita. A featured Views & Reviews acknowledges the discrepancy between standard of care for pediatric cancer and that of early-life epilepsies, and calls for the development and support of a national cooperative group: The Children's Epilepsy Group.

Articles

Preventive Antibiotics in Stroke Study (PASS):

A cost-effectiveness study

In a randomized, multicenter, open-label trial, the authors calculated the cost-effectiveness of preventive ceftriaxone for patients with acute stroke against standard stroke care (without preventive antimicrobial therapy). Preventive ceftriaxone was determined likely less costly than the standard treatment per unit decrease in modified Rankin Scale and per quality-adjusted life year gained.

Page 828

Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral sclerosis

In this study, patients with amyotrophic lateral sclerosis, compared to controls, displayed a larger amplitude of early cortical component (N20-P25) in the median nerve somatosensory evoked potential. Sensory cortex hyperexcitability was associated with shorter survival time in patients with amyotrophic lateral sclerosis, and might be a new prognostic biomarker.

Page 831

Demoralization in Parkinson disease

Demoralization is characterized by hopelessness and subjective incompetence. In this study, the authors assessed prevalence and associated features of demoralization in Parkinson disease (PD), finding an association with motor dysfunction and low PD-related life quality. Demoralization is treated with cognitive behavioral therapy, rather than antidepressants, and should be assessed by clinicians.

Page 835

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease

The authors confirm that REM sleep behavior disorder, excessive daytime sleepiness, autonomic symptoms, and lower cholinergic nucleus 4 (Ch4) density are associated with greater risk of future psychotic symptoms in Parkinson disease (PD). Reduced Ch4 density is also associated with nonmotor symptom burden. Ch4 measurement may be a neuroimaging biomarker in PD.

Page 836

MORE ONLINE

🎧 Editor's Summary

Audio summary of highlighted articles.

NPub.org/edsum

Continued

From editorialists Bohnen and Teipel: "The study by Barrett et al. provides novel information about associations between the integrity of the CBFB [cholinergic basal forebrain] and psychosis and autonomic symptoms in PD. Their observations suggest that the CBFB plays an important role in nonmotor symptoms in PD that are not limited to cognitive changes alone."

Page 823

NB: "Acute coronary syndrome associated with alemtuzumab infusion," p. 852. To check out other Clinical/Scientific Notes, point your browser to Neurology.org/N. At the end of the issue, check out the Resident & Fellow Right Brain article discussing the ethical considerations and consequences of the highly publicized case of an infant with mitochondrial DNA depletion syndrome. This week also includes a Reflections: Neurology and the Humanities poem titled "Subdural hematoma."

NEW EPISODE

May 1, 2018

CME Opportunity:

Listen to this week's *Neurology*® Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease (see p. 836)

1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease
2. What's Trending: Drug pricing

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, issue of *Neurology*. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the "What's Trending" segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.

Disclosures can be found at Neurology.org/podcast.

Neurology®

Spotlight on the May 1 issue

Robert A. Gross

Neurology 2018;90;817-818

DOI 10.1212/WNL.0000000000005402

This information is current as of April 30, 2018

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/90/18/817.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.